These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37341682)

  • 1. The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.
    Duminuco A; Vetro C; Giallongo C; Palumbo GA
    Expert Opin Pharmacother; 2023; 24(13):1449-1461. PubMed ID: 37341682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
    Tiribelli M; Morelli G; Bonifacio M
    Expert Opin Pharmacother; 2024 Apr; 25(6):743-754. PubMed ID: 38738513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational non-JAK inhibitors for chronic phase myelofibrosis.
    Bankar A; Gupta V
    Expert Opin Investig Drugs; 2020 May; 29(5):461-474. PubMed ID: 32245330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
    Tremblay D; Hoffman R
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in JAK2 inhibition for the treatment of myelofibrosis.
    Rippel N; Kremyanskaya M
    Expert Opin Pharmacother; 2024 Jun; 25(9):1175-1186. PubMed ID: 38919983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
    Loscocco GG; Vannucchi AM
    Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
    Edahiro Y
    Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-X
    Pemmaraju N; Garcia JS; Perkins A; Harb JG; Souers AJ; Werner ME; Brown CM; Passamonti F
    Cancer; 2023 Nov; 129(22):3535-3545. PubMed ID: 37584267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
    Mascarenhas JO; Verstovsek S
    Cancer; 2022 Jul; 128(14):2717-2727. PubMed ID: 35385124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
    England JT; Gupta V
    Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
    Hunter AM; Bose P
    Expert Opin Pharmacother; 2024 Jul; 25(10):1391-1404. PubMed ID: 39067001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
    Tefferi A; Pardanani A; Gangat N
    Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
    Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
    Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia in myelofibrosis: Current and emerging treatment options.
    Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
    Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
    Morsia E; Gangat N
    Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
    Waksal JA; Mascarenhas J
    Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.
    Arslan Davulcu E; Oğuz MB; Kılıç E; Eşkazan AE
    Expert Opin Investig Drugs; 2024 Jan; 33(1):27-37. PubMed ID: 38073183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress of JAK inhibitors for hematological disorders.
    Kirito K
    Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
    Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
    Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis.
    Ipek Y; Kilic B; Gunay UB; Eskazan AE
    Expert Opin Investig Drugs; 2023; 32(10):931-940. PubMed ID: 37811861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.